Avihepadnaviridae

Viral Hepatitis

Volumn , Issue , 2007, Pages 193-209

  Jilbert, Allison R ^a   Locarnini, Stephen A ^b  

^a Infectious Diseases Laboratories   (Australia)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

Avian hepadnaviral infections; Avihepadnaviridae; Mammalian hepadnaviruses; Pathology of infection; Woodchuck hepatitis virus (WHV)

Indexed keywords

EID: 84887609202     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987131.ch12     Document Type: Chapter

References (165)

1. Macdonald D, Holmes E, Lewis C, Simmonds P. Detection of hepatitis B virus infection in wild-born chimpanzees (Pan troglodytes verus): phylogenetic relationships with human and other primate genotypes. J Virol 2000;74:4253-7.
2. Robertson BH, Margolis HS. Primate hepatitis B viruses - genetic diversity, geography and evolution. Rev Med Virol 2002;12:133-41.
3. Zuckerman AJ, Thornton A, Howard CR, Tsiquaye KN, Jones DM, Brambell MR. Hepatitis B outbreak among chimpanzees at the London Zoo. Lancet 1978;2:652-44
4. Lanford RE, Chavez D, Barrera A, Brasky KM. An infectious clone of woolly monkey hepatitis B virus. J Virol 2003;77:7814-9.
5. Summers J, Smolec JM, Snyder R. A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks. Proc Natl Acad Sci USA 1978;75:4533-7.
6. Marion PL, Oshiro LS, Regnery DC, Scullard GH, Robinson WS. A virus in Beechey ground squirrels that is related to hepatitis B virus of humans. Proc Natl Acad Sci USA 1980;77:2941-5.
7. Testut P, Renard CA, Terradillos O et al. A new hepadnavirus endemic in arctic ground squirrels in Alaska. J Virol 1996;70:4210-19.
8. Miyakawa Y, Mizokami M. Classifying hepatitis B virus genotypes. Intervirology 2003;46:329-38.
9. Mason WS, Seal G, Summers J. Virus of Pekin ducks with structural and biological relatedness to human hepatitis B virus. J Virol 1980;36:829-36.
10. Sprengel R, Kaleta EF, Will H. Isolation and characterization of a hepatitis B virus endemic in herons. J Virol 1988;62:3832-9.
11. Pult I, Netter HJ, Bruns M et al. Identification and analysis of a new hepadnavirus in white storks. Virology 2001;289:114-28.
12. Chang SF, Netter HJ, Bruns M, Schneider R, Frolich K, Will H. A new avian hepadnavirus infecting snow geese (Anser caerulescens) produces a significant fraction of virions containing single-stranded DNA. Virology 1999;262:39-54.
13. Sprengel R, Schneider R, Marion PL, Fernholz D, Wildner G, Will H. Comparative sequence analysis of defective and infectious avian hepadnaviruses. Nucleic Acids Res 1991;19:4289.
14. Triyatni M, Ey P, Tran T et al. Sequence comparison of an Australian duck hepatitis B virus strain with other avian hepadnaviruses. J Gen Virol 2001;82:373-8.
15. Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986;47:451-60.
16. Wildner G, Fernholz D, Sprengel R, Schneider R, Will H. Characterization of infectious and defective cloned avian hepadnavirus genomes. Virology 1991;185:345-53.
17. Mangisa NP, Smuts HE, Kramvis A et al. Molecular characterization of duck hepatitis B virus isolates from South african ducks. Virus Genes 2004;28:179-86.
18. Ishikawa T, Ganem D. The pre-S domain of the large viral envelope protein determines host range in avian hepatitis B viruses. Proc Natl Acad Sci USA 1995;92:6259-63.
19. Chang SF, Netter HJ, Hildt E et al. Duck hepatitis B virus expresses a regulatory HBx-like protein from a hidden open reading frame. J Virol 2001;75:161-70.
20. Feitelson MA, Marion PL, Robinson WS. Core particles of hepatitis B virus and ground squirrel hepatitis virus. II. Characterization of the protein kinase reaction associated with ground squirrel hepatitis virus and hepatitis B virus. J Virol 1982;43:741-8.
21. Galibert F, Chen TN, Mandart E. Nucleotide sequence of a cloned woodchuck hepatitis virus genome: comparison with the hepatitis B virus sequence. J Virol 1982;41:51-65.
22. Gerlich WH, Feitelson MA, Marion PL, Robinson WS. Structural relationships between the surface antigens of ground squirrel hepatitis virus and human hepatitis B virus. J Virol 1980;36:787-95.
23. Mandart E, Kay A, Galibert F. Nucleotide sequence of a cloned duck hepatitis B virus genome: comparison with woodchuck and human hepatitis B virus sequences. J Virol 1984;49:782-92.
24. Marion PL. Use of animal models to study hepatitis B. Prog Med Virol 1988;35:43-75.
25. Werner BG, Smolec JM, Snyder R, Summers J. Serological relationship of woodchuck hepatitis virus to human hepatitis B virus. J Virol 1979;32:314-22.
26. Netter HJ, Chassot S, Chang SF, Cova L, Will H. Sequence heterogeneity of heron hepatitis B virus genomes determined by full-length DNA amplification and direct sequencing reveals novel and unique features. J Gen Virol 1997;78(Pt 7)):1707-18.
27. Meier P, Scougall CA, Will H, Burrell CJ, Jilbert AR. A duck hepatitis B virus strain with a knockout mutation in the putative X ORF shows similar infectivity and in vivo growth characteristics to wild-type virus. Virology 2003;317:291-8.
28. Jilbert AR, Kotlarski I. Immune responses to duck hepatitis B virus infection. Dev Comp Immunol 2000;24:285-302.
29. Marion PL, Cullen JM, Azcarraga RR, Van Davelaar MJ, Robinson WS. Experimental transmission of duck hepatitis B virus to Pekin ducks and to domestic geese. Hepatology 1987;7:724-31.
30. Pugh JC, Simmons H. Duck hepatitis B virus infection of Muscovy duck hepatocytes and nature of virus resistance in vivo. J Virol 1994;68:2487-94.
31. Cullen JM, Newbold J, Marion PL. Acute severe liver disease in duck hepatitis B virus infected domestic geese. In: Zuckerman A, ed. Viral Hepatitis and Liver Disease. New York: Alan R Liss, 1988:517-22.
32. Newbold JE, Cullen JM. Experimental transmission and subsequent replication of duck hepatitis B virus in domestic geese. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. New York: Alan R Liss, 1988:513-16.
33. Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982;29:403-15.
34. Pugh JC, Di Q, Mason WS, Simmons H. Susceptibility to duck hepatitis B virus infection is associated with the presence of cell surface receptor sites that efficiently bind viral particles. J Virol 1995;69:4814-22.
35. Kuroki K, Cheung R, Marion PL, Ganem D. A cell surface protein that binds avian hepatitis B virus particles. J Virol 1994;68:2091-6.
36. Breiner KM, Urban S, Schaller H. Carboxypeptidase D (gp180), a Golgi-resident protein, functions in the attachment and entry of avian hepatitis B viruses. J Virol 1998;72:8098-104.
37. Li J, Tong S, Wands JR. Identification and expression of glycine decarboxylase (p120) as a duck hepatitis B virus pre-S envelope- binding protein. J Biol Chem 1999;274:27658-65.
38. Li JS, Tong SP, Wands JR. Characterization of a 120-kilodalton pre-S-binding protein as a candidate duck hepatitis B virus receptor. J Virol 1996;70:6029-35.
39. Kock J, Borst EM, Schlicht HJ. Uptake of duck hepatitis B virus into hepatocytes occurs by endocytosis but does not require passage of the virus through an acidic intracellular compartment. J Virol 1996;70:5827-31.
40. Eckhardt SG, Milich DR, McLachlan A. Hepatitis B virus core antigen has two nuclear localization sequences in the argininerich carboxyl terminus. J Virol 1991;65:575-82.
41. Kann M, Sodeik B, Vlachou A, Gerlich WH, Helenius A. Phosphorylation- dependent binding of hepatitis B virus core particles to the nuclear pore complex. J Cell Biol 1999;145:45-55.
42. Yeh CT, Liaw YF, Ou JH. The arginine-rich domain of hepatitis B virus precore and core proteins contains a signal for nuclear transport. J Virol 1990;64:6141-7.
43. Pante N, Kann M. Nuclear pore complex is able to transport macromolecules with diameters of about 39 nm. Mol Biol Cell 2002;13:425-34.
44. Rabe B, Vlachou A, Pante N, Helenius A, Kann M. Nuclear import of hepatitis B virus capsids and release of the viral genome. Proc Natl Acad Sci USA 2003;100:9849-54.
45. Hruska JF, Clayton DA, Rubenstein JL, Robinson WS. Structure of hepatitis B Dane particle DNA before and after the Dane particle DNA polymerase reaction. J Virol 1977;21:666-72.
46. Bock CT, Schranz P, Schroder CH, Zentgraf H. Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell. Virus Genes 1994;8:215-29.
47. Bock CT, Schwinn S, Locarnini S et al. Structural organization of the hepatitis B virus minichromosome. J Mol Biol 2001;307:183-96.
48. Tagawa M, Omata M, Okuda K. Appearance of viral RNA transcripts in the early stage of duck hepatitis B virus infection. Virology 1986;152:477-82.
49. Buscher M, Reiser W, Will H, Schaller H. Transcripts and the putative RNA pregenome of duck hepatitis B virus: implications for reverse transcription. Cell 1985;40:717-24.
50. Huang M, Summers J. pet, a small sequence distal to the pregenome cap site, is required for expression of the duck hepatitis B virus pregenome. J Virol 1994;68:1564-72.
51. Crescenzo-Chaigne B, Pillot J, Lilienbaum A, Levrero M, Elfassi E. Identification of a strong enhancer element upstream from the pregenomic RNA start site of the duck hepatitis B virus genome. J Virol 1991;65:3882-6.
52. Liu C, Condreay LD, Burch JB, Mason W. Characterization of the core promoter and enhancer of duck hepatitis B virus. Virology 1991;184:242-52.
53. Beckel-Mitchener A, Summers J. A novel transcriptional element in circular DNA monomers of the duck hepatitis B virus. J Virol 1997;71:7917-22.
54. Lilienbaum A, Crescenzo-Chaigne B, Sall AA, Pillot J, Elfassi E. Binding of nuclear factors to functional domains of the duck hepatitis B virus enhancer. J Virol 1993;67:6192-200.
55. Liu C, Mason WS, Burch JB. Identification of factor-binding sites in the duck hepatitis B virus enhancer and in vivo effects of enhancer mutations. J Virol 1994;68:2286-96.
56. Jilbert AR, Burrell CJ, Triyatni M, Kann M. Hepatitis B Virus Replication. London: International Medical Press, 2002:43-5.
57. Huang MJ, Summers J. Infection initiated by the RNA pregenome of a DNA virus. J Virol 1991;65:5435-9.
58. Calvert J, Summers J. Two regions of an avian hepadnavirus RNA pregenome are required in cis for encapsidation. J Virol 1994;68:2084-90.
59. Hirsch R, Loeb D, Pollack J, Ganem D. cis-acting sequences required for encapsidation of duck hepatitis B virus pregenomic RNA. J Virol 1991;65:3309-16.
60. Ostrow KM, Loeb DD. Characterization of the cis-acting contributions to avian hepadnavirus RNA encapsidation. J Virol 2002;76:9087-95.
61. Lien JM, Aldrich CE, Mason WS. Evidence that a capped oligoribonucleotide is the primer for duck hepatitis B virus plusstrand DNA synthesis. J Virol 1986;57:229-36.
62. Lien JM, Petcu DJ, Aldrich CE, Mason WS. Initiation and termination of duck hepatitis B virus DNA synthesis during virus maturation. J Virol 1987;61:3832-40.
63. Mueller-Hill K, Loeb DD. cis-acting sequences 5E, M, and 3E interact to contribute to primer translocation and circularization during reverse transcription of avian hepadnavirus DNA. J Virol 2002;76:4260-6.
64. Liu N, Tian R, Loeb DD. Base pairing among three cis-acting sequences contributes to template switching during hepadnavirus reverse transcription. Proc Natl Acad Sci USA 2003;100:1984-9.
65. Habig JW, Loeb DD. Small DNA hairpin negatively regulates in situ priming during duck hepatitis B virus reverse transcription. J Virol 2002;76:980-9.
66. Habig JW, Loeb DD. The conformation of the 3' end of the minus-strand DNA makes multiple contributions to template switches during plus-strand DNA synthesis of duck hepatitis B virus. J Virol 2003;77:12401-11.
67. Loeb DD, Mack AA, Tian R. A secondary structure that contains the 5' and 3' splice sites suppresses splicing of duck hepatitis B virus pregenomic RNA. J Virol 2002;76:10195-202.
68. Tavis JE, Perri S, Ganem D. Hepadnavirus reverse transcription initiates within the stem-loop of the RNA packaging signal and employs a novel strand transfer. J Virol 1994;68:3536-43.
69. Tavis JE, Massey B, Gong Y. The duck hepatitis B virus polymerase is activated by its RNA packaging signal, epsilon. J Virol 1998;72:5789-96.
70. Wang GH, Seeger C. Novel mechanism for reverse transcription in hepatitis B viruses. J Virol 1993;67:6507-12.
71. Junker-Niepmann M, Bartenschlager R, Schaller H. A short cisacting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA. EMBO J 1990;9:3389-96.
72. Bartenschlager R, Schaller H. The amino-terminal domain of the hepadnaviral P-gene encodes the terminal protein (genome- linked protein) believed to prime reverse transcription. EMBO J 1988;7:4185-92.
73. Bosch V, Bartenschlager R, Radziwill G, Schaller H. The duck hepatitis B virus P-gene codes for protein strongly associated with the 5'-end of the viral DNA minus strand. Virology 1988;166:475-85.
74. Yang W, Summers J. Illegitimate replication of linear hepadnavirus DNA through nonhomologous recombinations. J Virol 1995;69:4029-36.
75. Yang W, Mason WS, Summers J. Covalently closed circular viral DNA formed from two types of linear DNA in woodchuck hepatitis virus-infected liver. J Virol 1996;70:4567-75.
76. Loeb DD, Hirsch R, Ganem D. Identification of factor-binding sites in the duck hepatitis B virus DNA synthesis in hepatitis B viruses: implications for other reverse transcribing elements. EMBO J 1991;10:3533-40.
77. Strapans S, Loeb D, Ganem D. Mutations affecting hepadnavirus plus strand DNA synthesis dissociate primer cleavage from translocation and reveal the origin of linear viral DNA. J Virol 1991;65:1255-62.
78. Yang W, Summers J. Integration of hepadnavirus DNA in infected liver: evidence for a linear precursor. J Virol 1999;73:9710-17.
79. Grgacic EV, Kuhn C, Schaller H. Hepatitis B virus envelope topology: insertion of a loop region in the membrane and role of S in L protein translocation. J Virol 2000;74:2455-8.
80. Grgacic EV. Identification of structural determinants of the first transmembrane domain of the small envelope protein of duck hepatitis B virus essential for particle morphogenesis. J Gen Virol 2002;83:1635-44.
81. Grgacic EV, Schaller H. A metastable form of the large envelope protein of duck hepatitis B virus: low-pH release results in a transition to a hydrophobic, potentially fusogenic conformation. J Virol 2000;74:5116-22.
82. Schlicht HJ, Salfeld J, Schaller H. The duck hepatitis B virus pre-C region encodes a signal sequence which is essential for synthesis and secretion of processed core proteins but not for virus formation. J Virol 1987;61:3701-9.
83. Schneider R, Fernholz D, Wildner G, Will H. Mechanism, kinetics, and role of duck hepatitis B virus e-antigen expression in vivo. Virology 1991;182:503-12.
84. Miller RH, Robinson WS. Hepatitis B virus DNA forms in nuclear and cytoplasmic fractions of infected human liver. Virology 1984;137:390-9.
85. Jilbert AR, Wu TT, England JM et al. Rapid resolution of duck hepatitis B virus infections occurs after massive hepatocellular involvement. J Virol 1992;66:1377-88.
86. Kajino K, Jilbert AR, Saputelli J, Aldrich CE, Cullen J, Mason WS. Woodchuck hepatitis virus infections: very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte. J Virol 1994;68:5792-803.
87. Wu TT, Coates L, Aldrich CE, Summers J, Mason WS. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology 1990;175:255-61.
88. Summers J, Smith PM, Horwich AL. Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J Virol 1990;64:2819-24.
89. Luscombe C, Pedersen J, Bowden S, Locarnini S. Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy. Liver 1994;14:182-92.
90. Wang Y, Bowden S, Shaw T et al. Inhibition of duck hepatitis B virus replication in vivo by the nucleoside analogue ganci clovir (9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine). Antiviral Chemistry and Chemotherapy 1991;2:107-14.
91. Lok AS. Treatment of chronic hepatitis B. J Viral Hepat 1994;1:105-24.
92. Mason WS, Halpern MS, England JM et al. Experimental transmission of duck hepatitis B virus. Virology 1983;131:375-84.
93. O’Connell AP, Urban MK, London WT. Naturally occurring infection of Pekin duck embryos by duck hepatitis B virus. Proc Natl Acad Sci USA 1983;80:1703-6.
94. Tsiquaye KN, Rapicetta M, McCaul TF, Zuckerman AJ. Experimental in ovo transmission of duck hepatitis B virus. J Virol Methods 1985;11:49-57.
95. Jilbert A, Botten JD, Miller DS et al. Characterisation of ageand dose-related outcomes of duck hepatitis B virus infection. Virology 1998;244:273-82.
96. Jilbert AR, Miller DS, Scougall CA, Turnbull H, Burrell CJ. Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks. Virology 1996;226:338-45.
97. Meier P, Scougall CA, Burrell CJ, Jilbert A. Analysis of infectivity and in vivo growth characteristics of a cytopathic duck hepatitis mutant, G133E. Proceedings of the 11th International Symposium of Viral Hepatitis and Liver Disease, 2004. (In press).
98. Lenhoff RJ, Luscombe CA, Summers J. Competition in vivo between a cytopathic variant and a wild-type duck hepatitis B virus. Virology 1998;251:85-95.
99. Lenhoff RJ, Luscombe CA, Summers J. Acute liver injury following infection with a cytopathic strain of duck hepatitis B virus. Hepatology 1999;29:563-71.
100. Bertram EM, Jilbert AR, Kotlarski I. Optimization of an in vitro assay which measures the proliferation of duck T lymphocytes from peripheral blood in response to stimulation with PHA and ConA. Dev Comp Immunol 1997;21:299-310.
101. Bertram EM, Jilbert AR, Kotlarski I. An homologous in vitro assay to detect lymphokines released by PHA-activated duck peripheral blood lymphocytes and spleen cells. Vet Immunol Immunopathol 1997;56:163-74.
102. Miller DS, Bertram EM, Scougall CA, Kotlarski I, Jilbert AR. Studying host immune responses against duck hepatitis B virus infection. Methods Mol Med 2004;96:3-25.
103. Bertram EM, Jilbert AR, Kotlarski I. Characterisation of duck thrombocytes. Res Vet Sci 1998;64:267-70.
104. Bertram EM, Wilkinson RG, Lee BA, Jilbert AR, Kotlarski I. Identification of duck T lymphocytes using an anti-human T cell (CD3) antiserum. Vet Immunol Immunopathol 1996;51:353-63.
105. Schultz U, Kock J, Schlicht HJ, Staeheli P. Recombinant duck interferon: a new reagent for studying the mode of interferon action against hepatitis B virus. Virology 1995;212:641-9.
106. Huang A, Scougall CA, Lowenthal JW, Jilbert AR, Kotlarski I. Structural and functional homology between duck and chicken interferon-gamma. Dev Comp Immunol 2001;25:55-68.
107. Schultz U, Chisari FV. Recombinant duck interferon gamma inhibits duck hepatitis B virus replication in primary hepatocytes. J Virol 1999;73:3162-8.
108. Jilbert AR, Freiman JS, Burrell CJ et al. Virus-liver cell interactions in duck hepatitis B virus infection. A study of virus dissemination within the liver. Gastroenterology 1988;95:1375-82.
109. Triyatni M, Jilbert AR, Qiao M, Miller DS, Burrell CJ. Protective efficacy of DNA vaccines against duck hepatitis B virus infection. J Virol 1998;72:84-94.
110. Summers J, Jilbert AR, Yang W et al. Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc Natl Acad Sci USA 2003;100:11652-9.
111. Robinson WS. Hepatocellular Mechanisms In Hepadnavirus-Infected Hosts. New York: Springer Verlag, 1994.
112. Marion PL, Knight SS, Ho BK, Guo YY, Robinson WS, Popper H. Liver disease associated with duck hepatitis B virus infection of domestic ducks. Proc Natl Acad Sci USA 1984;81:898-902.
113. Cova L, Wild CP, Mehrotra R et al. Contribution of aflatoxin B1 and hepatitis B virus infection in the induction of liver tumors in ducks. Cancer Res 1990;50:2156-63.
114. Cova L, Mehrotra R, Wild CP et al. Duck hepatitis B virus infection, aflatoxin B1 and liver cancer in domestic Chinese ducks. Br J Cancer 1994;69:104-9.
115. Cullen JM, Marion PL, Sherman GJ, Xin H, Newbold JE. Hepatic neoplasms in aflatoxin B1-treated congenitally DHBV-infected and virus-free Pekin Ducks. Cancer Res 1990;50:4072-80.
116. Lambert V, Cova L, Chevallier P, Mehrotra R, Trepo C. Natural and experimental infection of wild mallard ducks with duck hepatitis B virus. J Gen Virol 1991;72(Pt 2)):417-20.
117. Omata M, Uchiumi K, Ito Y et al. Duck hepatitis B virus and liver diseases. Gastroenterology 1983;85:260-7.
118. Yokosuka O, Omata M, Zhou YZ, Imazeki F, Okuda K. Duck hepatitis B virus DNA in liver and serum of Chinese ducks:integration of viral DNA in a hepatocellular carcinoma. Proc Natl Acad Sci USA 1985;82:5180-4.
119. Halpern MS, England JM, Deery DT, Petcu DJ, Mason WS, Molnar-Kimber KL. Viral nucleic acid synthesis and antigen accumulation in pancreas and kidney of Pekin ducks infected with duck hepatitis B virus. Proc Natl Acad Sci USA 1983;80:4865-9.
120. Jilbert AR, Freiman JS, Burrell C. Early virus cell interactions in duck hepatitis B virus infection. a time-course study of tissue tropism and sites of virus production. In: Zuckerman A, ed. Viral Hepatitis and Liver Disease. New York: Alan R Liss, 1988:497-500.
121. Tagawa M, Omata M, Yokosuka O, Uchiumi K, Imazeki F, Okuda K. Early events in duck hepatitis B virus infection. Sequential appearance of viral deoxyribonucleic acid in the liver, pancreas, kidney, and spleen. Gastroenterology 1985;89:1224-9.
122. Walter E, Teubner K, Blum HE, Offensperger WB, Offensperger S, Gerok W. Duck hepatitis B virus infection of non-hepatocytes. Liver 1991;11:53-62.
123. Tagawa M, Robinson WS, Marion PL. Duck hepatitis B virus replicates in the yolk sac of developing embryos. J Virol 1987;61:2273-9.
124. Dixon RJ, Jones NF, Freiman JS, Wilson NS. Natural infection of duck embryos with duck hepatitis B virus: time and tissue sequence of infection. J Med Virol 1989;29:303-7.
125. Halpern MS, Egan J, Mason WS, England JM. Viral antigen in endocrine cells of the pancreatic islets and adrenal cortex of Pekin ducks infected with duck hepatitis B virus. Virus Res 1984;1:213-23.
126. Halpern MS, Egan J, McMahon SB, Ewert DL. Duck hepatitis B virus is tropic for exocrine cells of the pancreas. Virology 1985;146:157-61.
127. Freiman JS, Jilbert AR, Dixon RJ et al. Experimental duck hepatitis B virus infection: pathology and evolution of hepatic and extrahepatic infection. Hepatology 1988;8:507-13.
128. England JM, Halpern MS. The arginine-stimulated insulin response is impaired in congenital duck hepatitis B virus infection. Virology 1988;165:299-302.
129. Jilbert AR, Freiman JS, Gowans EJ, Holmes M, Cossart YE, Burrell CJ. Duck hepatitis B virus DNA in liver, spleen, and pancreas: analysis by in situ and Southern blot hybridization. Virology 1987;158:330-8.
130. Torresi J, Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology 2000;118:S83-103.
131. Luscombe CA, Locarnini SA. The mechanism of action of antiviral agents in chronic hepatitis B. Viral Hepatitis Reviews 1996;1:1-35.
132. Lin E, Luscombe C, Wang Y, Shaw T, Locarnini S. The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother 1996;40:413-18.
133. Delmas J, Schorr O, Jamard C et al. Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrob Agents Chemother 2002;46:425-33.
134. Heijtink R, Kruining J, de Wilde G, Balzarini J, de Clercq E, Schalm S. Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob Agents Chemother 1994;38:2180-2.
135. Nicoll AJ, Colledge DL, Toole JJ, Angus PW, Smallwood RA, Locarnini SA. Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine (PMEA), an acyclic phosphonate nucleoside analogue. Antimicrob Agents Chemother 1998;42:3130-5.
136. Foster WK, Miller DS, Marion PL, Colonno RJ, Kotlarski I, Jilbert AR. Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection. Antimicrob Agents Chemother 2003;47:2624-35.
137. Marion PL, Salazar FH, Winters MA, Colonno RJ. Potent effi- cacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob Agents Chemother 2002;46:82-8.
138. Hafkemeyer P, Keppler-Hafkemeyer A, al Haya MA et al. Inhibition of duck hepatitis B virus replication by 2', 3'-dideoxy-3'-fluoroguanosine in vitro and in vivo. Antimicrob Agents Chemother 1996;40:792-4.
139. Lofgren B, Vickery K, Zhang YY, Nordenfelt E. 2', 3'-dideoxy-3'-fluoroguanosine inhibits duck hepatitis B virus in vivo. J Viral Hepat 1996;3:61-5.
140. Fourel I, Cullen JM, Saputelli J et al. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J Virol 1994;68:8321-30.
141. Doong S, Tsai C, Schinazi R, Liotta D, Cheng Y. Inhibition of the replication of hepatitis B virus in vitro by 2', 3'-dideoxy-3'-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991;88:8495-9.
142. Le Guerhier F, Pichoud C, Guerret S et al. Characterization of the antiviral effect of 2', 3'-dideoxy-2', 3'-didehydro-beta-L-5- fluorocytidine in the duck hepatitis B virus infection model. Antimicrob Agents Chemother 2000;44:111-22.
143. Cullen JM, Marion PL, Newbold JE. A sequential histological and immunohistochemical study of duck hepatitis B infection in Pekin ducks. Vet Pathol 1989;26:164-72.
144. Fourel I, Saputelli J, Schaffer P, Mason WS. The carbocyclic analog of 2'-deoxyguanosine induces a prolonged inhibition of duck hepatitis B virus DNA synthesis in primary hepatocyte cultures and in the liver. J Virol 1994;68:1059-65.
145. Haritani H, Uchida T, Okuda Y, Shikata T. Effect of 3'-azido-3'- deoxythymidine on replication of duck hepatitis B virus in vivo and in vitro. J Med Virol 1989;29:244-8.
146. Heijtink R, De Wilde G, Kruining J et al. Inhibitory effect of 9-(2- phosphonoyl-methoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res 1993;21:141-53.
147. Hirota K, Sherker AH, Omata M, Yokosuka O, Okuda K. Effects of adenine arabinoside on serum and intrahepatic replicative forms of duck hepatitis B virus in chronic infection. Hepatology 1987;7:24-8.
148. Aguesse-Germon S, Liu SH, Chevallier M et al. Inhibitory effect of 2'-fluoro-5-methyl-beta-L-arabinofuranosyl-uracil on duck hepatitis B virus replication. Antimicrob Agents Chemother 1998;42:369-76.149
149. Lee B, Luo W, Suzuki S, Robins M, Tyrrell D. In vitro and in vivo comparison of the abilities of purine and pyrimidine 2', 3'- dideoxynucleosides to inhibit duck hepadnavirus. Antimicrob Agents Chemother 1989;33:336-9.
150. Lin E, Luscombe C, Colledge D, Wang YY, Locarnini S. Long term therapy with the guanosine nucleoside analogue penciclovir controls chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother 1998;42:2132-7.
151. Mason WS, Cullen J, Saputelli J et al. Characterization of the antiviral effects of 2' carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus. Hepatology 1994;19:398-411.
152. Niu J, Wang Y, Qiao M et al. Effect of Phyllanthus amarus on duck hepatitis B virus replication in vivo. J Med Virol 1990;32:212-18.
153. Shaw T, Locarnini SA. Preclinical aspects of lamivudine and famciclovir against hepatitis B virus. J Viral Hepat 1999;6:89-106.
154. Sherker AH, Hirota K, Omata M, Okuda K. Foscarnet decreases serum and liver duck hepatitis B virus DNA in chronically infected ducks. Gastroenterology 1986;91:818-24.
155. Tsiquaye K, Slomka M, Maung M. Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo. J Med Virol 1994;42:306-10.
156. Le Guerhier F, Thermet A, Guerret S et al. Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model. J Hepatol 2003;38:328-34.
157. Locarnini SA, Civitico GM, Newbold JE. Hepatitis B: new approaches for antiviral chemotherapy. Antiviral Chemistry and Chemotherapy 1996;7:1-12.
158. Luscombe C, Pedersen J, Uren E, Locarnini S. Longterm ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: effect on intrahepatitic viral DNA, RNA and protein expression. Hepatology 1996;24:766-73.
159. Yokosuka O, Omata M, Imazeki F, Okuda K, Summers J. Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment: analysis of intrahepatic replicative hepatitis B virus DNA. Hepatology 1985;5:728-34.
160. Civitico G, Wang YY, Luscombe C et al. Antiviral strategies in chronic hepatitis B virus infection: II. Inhibition of duck hepatitis B virus in vitro using conventional antiviral agents and supercoiled-DNA active compounds. J Med Virol 1990;31:90-7.
161. Gabrielli BG, Johnstone RW, Saunders NA. Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: a work in progress. Curr Cancer Drug Targets 2002;2:337-53.
162. Kelly WK, O’Connor OA, Marks PA. Histone deacetylase inhibitors:from target to clinical trials. Expert Opin Investig Drugs 2002;11:1695-713.
163. Szyf M, Slack AD. Mechanisms of epigenetic silencing of the c21 gene in Y1 adrenocortical tumor cells. Endocr Res 2000;26:921-30.
164. Wang Y, Luscombe C, Bowden S, Shaw T, Locarnini S. Inhibition of duck hepatitis B virus DNA replication by ganciclovir and nalidixic acid antiviral chemotherapy. Antimicrob Agents Chemother 1995;39:556-8.
165. Niu J, Wang Y, Dixon R et al. The use of ampligen alone and in combination with ganciclovir and coumermycin A1 for the treatment of ducks congenitally-infected with duck hepatitis B virus. Antiviral Res 1993;21:155-71.